Mediatech Expands Corning cellgro® Serum-free Offerings with hybriGRO SF™

  • Email
  • Print

hybriGRO SF™ medium enhances hybridoma protein and monoclonal antibody production

MANASSAS, Va., July 6, 2012 --Mediatech Inc., a subsidiary of Corning Incorporated (NYSE:GLW), announced today the introduction of hybriGRO SF™, which enhances the performance of monoclonal antibody-producing hybridoma cells.

Monoclonal antibodies (mAbs) derived from hybridoma cells (cells formed from the fusion of antibody-producing B-cells with myeloma cells) are used extensively in the prevention, diagnosis, and treatment of cancers and other diseases.

hybriGRO SF™ is an advanced serum-free (SF) and animal-derived component-free (ADCF) defined medium which provides the consistency demanded of a defined media in commercial mAb production.

“The use of serum- and animal-origin free defined media is critical in the culture of hybridoma cells for the production of monoclonal antibodies. Our data shows that hybriGRO SF provides a significant increase in cell viability and protein production over existing defined media, with strong protein-product stability in long-term culture,” said Jason Walsh, business director of Mediatech. “The release of hybriGRO SF is a key addition to the Corning cellgro® serum-free portfolio, supporting the needs of life scientists ranging from basic research to biopharmaceutical production.”

In December 2011, Corning acquired Mediatech, which produces the full range of Corning cellgro® media and supplements that are available through Corning Life Sciences sales force and its authorized distributors.

Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effect of global political, economic and business conditions; conditions in the financial and credit markets; currency fluctuations; tax rates; product demand and industry capacity; competition; reliance on a concentrated customer base; manufacturing efficiencies; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.

About Corning Incorporated

Corning Incorporated (www.corning.com) is the world leader in specialty glass and ceramics. Drawing on more than 160 years of materials science and process engineering knowledge, Corning creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications and life sciences. Our products include glass substrates for LCD televisions, computer monitors and laptops; ceramic substrates and filters for mobile emission control systems; optical fiber, cable, hardware & equipment for telecommunications networks; optical biosensors for drug discovery; and other advanced optics and specialty glass solutions for a number of industries including semiconductor, aerospace, defense, astronomy, and metrology.

About Mediatech Inc.

Mediatech, Inc., (www.cellgro.com), a Corning subsidiary, is a leading provider of media, supplements and related solutions and other products to support scientific research, biotechnology, pharmaceutical development, the diagnosis of disease. In addition to a broad product line of liquid and powder products, Mediatech also develops, manufactures and supplies custom culture and bioprocess products and flexible packaging to meet specific customer needs. Mediatech is a cGMP facility, compliant with FDA regulations 21 CFR Part 820 and certified to ISO 13485:2003. Mediatech’s Corning cellgro brand product portfolio is available through the Corning Life Sciences sales force and distribution partners.

  • <<
  • >>